Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
In other clinical studies, ON 01910.Na has been safely given intravenously to Patients with
advanced cancers. However, to treat some Patients, it may be better if ON 01910.Na could be
given by mouth. This study will determine if it is safe to give ON 01910.Na by mouth, what is
the highest dose can be safely given by mouth, and how much of the drug gets from the stomach
into the blood stream when it is given by mouth.